CAS Number61718-82-9
Synonyms(E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone 2-aminoethyloxime maleate; MFCD00269809; EINECS 228-994-3; DU 23000 {Maleate}; faverin50; Fluvoxamine Maleat; Fluvoxamine (maleate); SME 3110 {Maleate}; (E)-fluvoxamine maleate; MK 264 {Maleate}; Fluvoxamine maleate; MK-264; Faverin; Floxyfral; Maveral; Dumirox; (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-2-aminoethyl oxime maleate; Luvox; Fevarin
Molecular FormulaC19H25F3N2O6
Molecular Weight434.41
Purity98.00%
Boiling Point370.6ºC at 760 mmHg
Melting Point120-121.5ºC
AppearanceWhite crystalline powder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 61718-82-9 |
| Catalog No. | 2A-9045540 |
| Chinese Name | 马来酸氟伏沙明 |
| Synonyms | (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone 2-aminoethyloxime maleate; MFCD00269809; EINECS 228-994-3; DU 23000 {Maleate}; faverin50; Fluvoxamine Maleat; Fluvoxamine (maleate); SME 3110 {Maleate}; (E)-fluvoxamine maleate; MK 264 {Maleate}; Fluvoxamine maleate; MK-264; Faverin; Floxyfral; Maveral; Dumirox; (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-2-aminoethyl oxime maleate; Luvox; Fevarin |
| Molecular Formula | C19H25F3N2O6 |
| Molecular Weight | 434.41 |
| Purity | 98.00 |
| Boiling Point | 370.6ºC at 760 mmHg |
| Melting Point | 120-121.5ºC |
| Appearance | White crystalline powder |
| Water Solubility | H2O: soluble |
| Storage Condition | 2-8°C |
| Application | Fluvoxamine maleate is a serotonin reuptake inhibitor with antidepressant activity. |
| HTC | 2928000090 |
| PubChem ID | 329831192 |
| SMILES | COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1.O=C(O)C=CC(=O)O |
| InChI | InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1- |
| InChI Key | LFMYNZPAVPMEGP-PIDGMYBPSA-N |
| Hazard Symbols | transportation |
| Bioactivity | Fluvoxamine maleate is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor.Target: SSRIsFluvoxamine (maleate) is the maleate salt form of fluvoxamine, which is effective in inhibiting 5-HT uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine [1]. fluvoxamine appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted [2]. Fluvoxamine was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation [ED50: 4.0 (2.7-5.9) and 5.1 (4.3-6.0)]. Effects on food were similar under each condition in which food was available. The results demonstrate that the potency of fluvoxamine in reducing ethanol-maintained behavior depends on whether ethanol is available in isolation or in the context of concurrently scheduled food reinforcement [3].Clinical indications: Depression; Obsessive compulsive disorder; Social phobia " FDA Approved Date: December 5, 1994Toxicity: Anorexia, Constipation, Dry mouth, Headache, Nausea, Nervousness, Skin rash, Sleep problems, Somnolence, Liver toxicity, Mania, Increase urination, Seizures, Sweating increase, Tremors, or Tourette's syndrome. Related Catalog Signaling Pathways >> Neuronal Signaling >> Serotonin Transporter Research Areas >> Neurological Disease References [1]. Ginsburg, B.C., J.W. Pinkston, and R.J. Lamb, The potency of fluvoxamine to reduce ethanol self-administration decreases with concurrent availability of food. Behav Pharmacol, 2012. 23(2): p. 134-42. [2]. Claassen, V., et al., Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol, 1977. 60(4): p. 505-16. [3]. Escalona, R., et al., Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety, 2002. 15(1): p. 29-33. Chemical & Physical Properties Boiling Point 370.6ºC at 760 mmHg Melting Point 120-121.5ºC Molecular Formula C19H25F3N2O6 Molecular Weight 434.407 Flash Point 177.9ºC Exact Mass 434.166473 PSA 131.44000 LogP 3.61360 InChIKey LFMYNZPAVPMEGP-PIDGMYBPSA-N SMILES COCCCCC(=NOCCN)c1ccc(C(F)(F)F)cc1.O=C(O)C=CC(=O)O Storage condition 2-8°C Water Solubility H2O: soluble |
| Use of | Fluvoxamine maleate is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor.Target: SSRIsFluvoxamine (maleate) is the maleate salt form of fluvoxamine, which is effective in inhibiting 5-HT uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine [1]. fluvoxamine appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted [2]. Fluvoxamine was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation [ED50: 4.0 (2.7-5.9) and 5.1 (4.3-6.0)]. Effects on food were similar under each condition in which food was available. The results demonstrate that the potency of fluvoxamine in reducing ethanol-maintained behavior depends on whether ethanol is available in isolation or in the context of concurrently scheduled food reinforcement [3].Clinical indications: Depression; Obsessive compulsive disorder; Social phobia " FDA Approved Date: December 5, 1994Toxicity: Anorexia, Constipation, Dry mouth, Headache, Nausea, Nervousness, Skin rash, Sleep problems, Somnolence, Liver toxicity, Mania, Increase urination, Seizures, Sweating increase, Tremors, or Tourette's syndrome. Properties Articles35 Name Fluvoxamine maleate Synonym More Synonyms Fluvoxamine maleat Biological Activity Description Fluvoxamine maleate is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor.Target: SSRIsFluvoxamine (maleate) is the maleate salt form of fluvoxamine, which is effective in inhibiting 5-HT uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine [1]. fluvoxamine appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted [2]. Fluvoxamine was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation [ED50: 4.0 (2.7-5.9) and 5.1 (4.3-6.0)]. Effects on food were similar under each condition in which food was available. The results demonstrate that the potency of fluvoxamine in reducing ethanol-maintained behavior depends on whether ethanol is available in isolation or in the context of concurrently scheduled food reinforcement [3].Clinical indications: Depression; Obsessive compulsive disorder; Social phobia " FDA Approved Date: December 5, 1994Toxicity: Anorexia, Constipation, Dry mouth, Headache, Nausea, Nervousness, Skin rash, Sleep problems, Somnolence, Liver toxicity, Mania, Increase urination, Seizures, Sweating increase, Tremors, or Tourette's syndrome. Related Catalog Signaling Pathways >> Neuronal Signaling >> Serotonin Transporter Research Areas >> Neurological Disease References [1]. Ginsburg, B.C., J.W. Pinkston, and R.J. Lamb, The potency of fluvoxamine to reduce ethanol self-administration decreases with concurrent availability of food. Behav Pharmacol, 2012. 23(2): p. 134-42. [2]. Claassen, V., et al., Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol, 1977. 60(4): p. 505-16. [3]. Escalona, R., et al., Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety, 2002. 15(1): p. 29-33. Chemical & Physical Properties Molecular Formula C19H25F3N2O6 Exact Mass 434.166473 PSA 131.44000 LogP 3.61360 InChIKey LFMYNZPAVPMEGP-PIDGMYBPSA-N Water Solubility H2O: soluble |
| Tax Rebate | 9.0% |
| Supervision | none |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Nandrolone sulfate sodium salt | 60672-82-4 | 2A-9045365 |
| Teicoplanin | 61036-62-2 | 2A-9045419 |
| Teicoplanin A2 | 61036-64-4 | 2A-9045420 |
| Mirtazapine | 61337-67-5 | 2A-9045477 |
| Rifapentine | 61379-65-5 | 2A-9045488 |
| (R,S)-4-Hydroxycyclophosphamide | 61903-30-8 | 2A-9045607 |
| Aspirin DL-lysine | 62952-06-1 | 2A-9045801 |
| Estradiol-3-benzoate-17-butyrate | 63042-18-2 | 2A-9045822 |
| Oxaliplatin | 63121-00-6 | 2A-9045841 |
| Penicillin V Benzathine | 63690-57-3 | 2A-9045951 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS